ESTRO 2024 - Abstract Book

S3551

Physics - Dose prediction, optimisation and applications of photon and electron planning

ESTRO 2024

CLINAC iX

68.19

0.96

PTV D95%

HALCYON

69.19

0.76

0.182

CLINAC iX

69.02

0.76

PTV D50%

HALCYON

71.10

0.74

0.442

CLINAC iX

71.31

0.73

PTV D2%

HALCYON

73.13

0.75

0.528

CLINAC iX

73.22

0.62

HI

HALCYON

0.06

0.013

0.041

CLINAC iX

0.07

0.013

CI

HALCYON

0.93

0.03

<0.001

CLINAC iX

0.91

0.03

Brain Stem PRV

HALCYON

35.37

9.26

0.176

CLINAC iX

36.82

6.93

Spinal Cord PRV

HALCYON

38.82

5.15

0.289

CLINAC iX

38.40

5.13

Mandible

HALCYON

71.43

6.33

0.841

CLINAC iX

71.48

5.92

Parotid Right

HALCYON

28.89

6.08

0.072

CLINAC iX

27.34

4.76

Parotid Left

HALCYON

27.25

7.22

0.773

CLINAC iX

27.53

4.55

Oral Cavity

HALCYON

36.43

8.26

0.091

CLINAC iX

36.00

8.13

Delivery Time

HALCYON

1.51

0.03

<0.001

CLINAC iX

1.48

0.03

Integral Dose

HALCYON

165.58

27.17

<0.001

CLINAC iX

167.82

26.34

Monitor Units

HALCYON

578.08

64.24

<0.001

CLINAC iX

642.95

78.38

Conclusion:

HALCYON plans are superior than CLINAC iX plans for locally advanced head and neck cancer with regard to parameters such as Homogeneity Index (HI), Conformity Index (CI), Intergral dose, monitoring units (MU) and treatment delivery time, but not with target coverage and doses to OARs. These results assured that HALCYON plans are suitable for head and neck cancer.

Keywords: halcyon, clinac ix